Skip to main content
SpringerLink
Log in

Peyronie’s Disease

  • Chapter
  • First Online:
Cancer and Sexual Health

Part of the book series: Current Clinical Urology ((CCU))

  • 1570 Accesses

Abstract

Peyronie’s disease (PD) is a psychologically and physically devastating disorder that is manifest by a fibrous inelastic scar of the tunica albuginea, resulting in palpable penile lesion in the flaccid condition and causing penile deformity including penile curvature, hinging, narrowing, shortening, and painful erections. In spite of multiple treatment options offered since Francois de la Peyronie described PD in 1743 [1]. PD remains a considerable therapeutic dilemma even to today’s practicing physicians.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 219.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 279.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 279.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. La Peyronie F. Sur quelques obstaclesqui sópposent à l’éjaculation nautrelle de la semence. Mem Acad Royale Chir. 1743;1:337–42.

    Google Scholar 

  2. Akkus E. Historical review of Peyronie’s disease. In: Levine LA, Levine LA, editors. Peyronie’s disease a guide to clinical management. Totowa, NJ: Humana; 2007.

    Google Scholar 

  3. Borgogni T. Cyrurgia Edita et Compilata. Venice, 1498 (written 1265–1275).

    Google Scholar 

  4. Murphy LJT. Miscellanea: Peyronie’s disease (fibrous cavernositis). In: The history of urology. 1st ed. Springfield, IL: Charles C. Thomas, 1972. p. 485–6.

    Google Scholar 

  5. Wesson MD. Peyronie’s disease (plastic induration) cause and treatment. J Urol. 1943;49:350–6.

    Google Scholar 

  6. Devine Jr CJ, Somers KD, Jordan SG, Schlossberg SM. Proposal: trauma as the cause of the Peyronie’s lesion. J Urol. 1997;157(1):285–90.

    Article  PubMed  Google Scholar 

  7. Zargooshi J. Trauma as the cause of Peyronie’s disease: penile fracture as a model of trauma. J Urol. 2004;172(1):186–8.

    Article  PubMed  Google Scholar 

  8. DiPietro LA. Wound healing: the role of the macrophage and other immune cells. Shock. 1995;4:233.

    Article  PubMed  CAS  Google Scholar 

  9. Ravanti L, Kahari VM. Matrix metalloproteinases in wound repair. Int J Mol Med. 2000;6:391–407.

    PubMed  CAS  Google Scholar 

  10. El Sakka AI, Hassoba HM, Chui RM. An animal model of Peyronie’s like condition associated with an increase of transforming growth factor b mRNA and protein expression. J Urol. 1997;158:2284–90.

    Article  PubMed  Google Scholar 

  11. Kucharewicz I, Kowal K, Buczko W, et al. The plasmin system in airway remodeling. Thromb Res. 2003;112:1–7.

    Article  PubMed  Google Scholar 

  12. Van de Water L. Mechanisms by which fibrin and fibronectin appear in healing wounds: implications for Peyronie’s disease. J Urol. 1997;157:306–10.

    Article  PubMed  Google Scholar 

  13. Davila H, Magee TR, Rajfer J, et al. Peyronie’s disease is associated with an increase of plasminogen activator inhibitor-1 in fibrotic plaque. Urology. 2005;65:645–8.

    Article  PubMed  Google Scholar 

  14. Davila H, Ferrini M, Rajfer J, et al. Fibrin induction of a Peyronie’s-like plaque in the rat penile tunica albuginea. BJU Int. 2003;91:830–8.

    Article  PubMed  CAS  Google Scholar 

  15. Qian A, Meals RA, Rajfer J, et al. Comparison of gene expression profiles between Peyronie’s disease and Dupuytren’s contracture. Urology. 2004;64(2):399–404.

    Article  PubMed  CAS  Google Scholar 

  16. Levine LA, Greenfield JM. Establishing a standardized evaluation of the man with Peyronie’s disease. Int J Impot Res. 2003;15(5):103–12.

    Article  Google Scholar 

  17. Savoie M, Kim SS, Soloway MS. A prospective study measuring penile length in men treated with radical prostatectomy for prostate cancer. J Urol. 2003;169(4):1462–4.

    Article  PubMed  Google Scholar 

  18. Moreland RB. Is there a role of hypoxemia in penile fibrosis: a viewpoint presented to the Society for the Study of Impotence. Int J Impot Res. 1998;10(2):113–20.

    Article  PubMed  CAS  Google Scholar 

  19. Moreland RB, Traish A, McMillin MA. PGE1 ­suppresses the induction of collagen synthesis by ­transforming growth factor-beta 1 in human corpus cavernosum smooth muscle. J Urol. 1995;153(3 Pt 1):826–34.

    PubMed  CAS  Google Scholar 

  20. Leungwattanakij S, Bivalacqua TJ, Usta MF, et al. Cavernous neurotomy causes hypoxia and fibrosis in rat corpus cavernosum. J Androl. 2003;24(2):239–45.

    PubMed  Google Scholar 

  21. Ciancio SJ, Kim ED. Penile fibrotic changes after radical retropubic prostatectomy. BJU Int. 2000;85:101.

    Article  PubMed  CAS  Google Scholar 

  22. Tal R, Heck M, Teloken P, et al. Peyronie’s disease following radical prostatectomy: incidence and predictors. J. Anrol. 2010;7(3):1254–61

    Google Scholar 

  23. Valente EG, Vernet D, Ferrini M, et al. L-Arginine and phosphodiesterase (PDE) inhibitors counteract fibrosis in the Peyronie’s fibrotic plaque and related fibroblast cultures. Nitric Oxide. 2003;9:229–44.

    Article  PubMed  CAS  Google Scholar 

  24. Dean BWO, Lue TF RC. Treatment of Peyronie’s disease with oral pentoxifylline. Nat Clin Pract Urol. 2006;3:111–5.

    Article  PubMed  Google Scholar 

  25. Akkus E, Carrier S, Rehman J, et al. Is colchicine effective in Peyronie’s disease? A pilot study. Urology. 1994;44:291–5.

    Article  PubMed  CAS  Google Scholar 

  26. Kadioglu A, Tefekli A, Koksal T, et al. Treatment of Peyronie’s disease with oral colchicine: long term results and predictive parameters of successful outcome. Int J Impot Res. 2000;12:169–75.

    Article  PubMed  CAS  Google Scholar 

  27. Safarinejad MR. Therapeutic effects of colchicine in the management of Peyronie’s disease: a randomized double-blind, placebo-controlled study. Int J Impot Res. 2004;16:238–43.

    Article  PubMed  CAS  Google Scholar 

  28. Zarafonetis CJ, Horrax TM. Treatment of Peyronie’s disease with potassium para-aminobenzoate (potaba). J Urol. 1959;81:770–2.

    PubMed  CAS  Google Scholar 

  29. Hasche-Klunder R. Treatment of peyronie’s disease with para-aminobenzoacidic potassium (POTOBA) [author’s transl]. Urologe A. 1978;17:224–7.

    PubMed  CAS  Google Scholar 

  30. Weidner W, Schroeder-Printzen I, Rudnick J. Randomized prospective placebo-controlled therapy of Peyronie’s disease (IPP) with Potaba (aminobenzoate potassium). J Urol. 1999;6:205.

    Article  Google Scholar 

  31. Weidner W, Hauck EW, Schnitker J. Potassium paraaminobenzoate (Potaba) in the treatment of Peyronie’s disease: a prospective, placebo-controlled, randomized study. Eur Urol. 2005;47:530–5.

    Article  PubMed  CAS  Google Scholar 

  32. Martin DJ, Badwan K, Parker M, et al. Transdermal application of verapamil gel to the penile shaft fails to infiltrate the tunica albuginea. J Urol. 2002;168:2483–5.

    Article  PubMed  CAS  Google Scholar 

  33. Fitch WP, Easterling J, Talbert RL, et al. Topical Verapamil HCl, topical Trifluoperazine, and topical magnesium sulfate for the treatment of Peyronie’s disease – A Placebo-Controlled Pilot Study. J Sex Med. 2007;4:477–84.

    Article  PubMed  CAS  Google Scholar 

  34. Levine LA. Comment on Topical Verpamil HCl, topical Trfluoperazine, and topical magnesium sulfate for the treatment of Peyronie’s disease – A Placebo-Controlled Pilot Study. J Sex Med. 2007;4:1081–2.

    Article  PubMed  Google Scholar 

  35. Riedl CR, Plas E, Engelhard P, et al. Iontophoresis for treatment of Peyronie’s disease. J Urol. 2000;163:95–9.

    Article  PubMed  CAS  Google Scholar 

  36. Montorsi F, Salonia A, Guazzoni G, et al. Transdermal electromotive multi-drug administration for Peyronie’s disease: preliminary results. J Androl. 2000;21:85–90.

    PubMed  CAS  Google Scholar 

  37. Di Stasi SM, Giannantoni A, Capelli G, et al. Transdermal electromotive administration of verapamil and dexamethasone for Peyronie’s disease. BJU Int. 2003;91:825–9.

    Article  PubMed  Google Scholar 

  38. Di Stasi SM, Giannantoni A, Stephen RL, et al. A prospective, randomized study using transdermal electromotive administration of verapamil and dexamethasone for Peyronie’s disease. J Urol. 2004;171:1605–8.

    Article  PubMed  Google Scholar 

  39. Levine LA, Estrada CR, Show W, et al. Tunica albuginea tissue analysis after electromotive drug administration. J Urol. 2003;169:1775–8.

    Article  PubMed  CAS  Google Scholar 

  40. Greenfield JM, Shah SJ, Levine LA. Verapamil vs. saline in electromotive drug administration (EDMA) for Peyronie’s disease: a double blind, placebo controlled trial. J Urol. 2007;177:972–5.

    Article  PubMed  CAS  Google Scholar 

  41. Ojingwa JC, Isseroff RR. Electrical stimulation of wound healing. J Invest Dermatol. 2003;121:1–12.

    Article  PubMed  CAS  Google Scholar 

  42. Bodner H, Howard AH, Kaplan JH. Peyronie’s disease: cortisone-hyaluronidase-hydrocortisone therapy. J Urol. 1954;72:400–3.

    PubMed  CAS  Google Scholar 

  43. Winter CC, Khanna R. Peyronie’s disease: results with dermo-jet injection of dexamethasone. J Urol. 1975;114:898–900.

    PubMed  CAS  Google Scholar 

  44. Williams G, Green NA. The non-surgical treatment of Peyronie’s disease. Br J Urol. 1980;52:392–5.

    Article  PubMed  CAS  Google Scholar 

  45. Gelbard MK, Walsh R, Kaufman JJ. Collagenase for Peyronie’s disease experimental studies. Urol Res. 1982;10:135–40.

    Article  PubMed  CAS  Google Scholar 

  46. Gelbard MK, Linkner A, Kaufman JJ. The use of collagenase in the treatment of Peyronie’s disease. J Urol. 1985;134:280–3.

    PubMed  CAS  Google Scholar 

  47. Gelbard MK, James K, Riach P, Dorey F. Collagenase vs. placebo in the treatment of Peyronie’s disease: a double blind study. J Urol. 1993;149:56–8.

    PubMed  CAS  Google Scholar 

  48. Roth M, Eickelberg O, Kohler E, et al. Ca2+ channel blockers modulate metabolism of collagens within the extracellular matrix. Proc Natl Acad Sci USA. 1996;93:5478–82.

    Article  PubMed  CAS  Google Scholar 

  49. Mulhall JP, Anderson MS, Lubrano T, et al. Peyronie’s disease cell culture models: phenotypic, genotypic and functional analyses. Int J Impot Res. 2002;14:397–405.

    Article  PubMed  CAS  Google Scholar 

  50. Levine LA, Merrick PF, Lee RC. Intralesional verapamil injection for the treatment of Peyronie’s disease. J Urol. 1994;151:1522–4.

    PubMed  CAS  Google Scholar 

  51. Rehman J, Benet A, Melman A. Use of intralesional verapamil to dissolve Peyronie’s disease plaque: a long term single-blind study. Urology. 1998;51:620–6.

    Article  PubMed  CAS  Google Scholar 

  52. Levine LA, Estrada CR. Intralesional verapamil for the treatment of Peyronie’s disease: a review. Int J Impot Res. 2002;14:324–8.

    Article  PubMed  CAS  Google Scholar 

  53. Bennett NE, Guhring P, Mulhall JP. Intralesional verapamil prevents the progression of Peyronie’s disease. Urology. 2007;69:1181–4.

    Article  PubMed  Google Scholar 

  54. Duncan MR, Berman B, Nseyo UO. Regulation of the proliferation and biosynthetic activities of cultured human Peyronie’s disease fibroblasts by interferons-αβ and γ. Scand J Urol Nephrol. 1991;25:89–94.

    Article  PubMed  CAS  Google Scholar 

  55. Wegner HE, Andreson R, Knipsel HH, et al. Treatment of Peyronie’s disease with local interferon-α-2b. Eur Urol. 1995;28:236–40.

    PubMed  CAS  Google Scholar 

  56. Wegner HE, Andresen R, Knipsel HH, et al. Local interferon-α-2b is not an effective treatment in early-stage Peyronie’s disease. Eur Urol. 1997;32:190–3.

    PubMed  CAS  Google Scholar 

  57. Ahuja S, Bivalacqua TJ, Case J, Vincent M, Sikka SC, Hellstrom WJ. A pilot study demonstrating clinical benefit from intralesional interferon alpha 2B in the treatment of Peyronie’s disease. J Androl. 1999;20:444–8.

    PubMed  CAS  Google Scholar 

  58. Dang G, Matern R, Bivalacqua TJ, et al. Intralesional interferon-α-2b injections for the treatment of Peyronie’s disease. South Med J. 2004;97:42–6.

    Article  PubMed  Google Scholar 

  59. Hellstrom WJ, Kendirici M, Matern R, et al. Single-blind, multicenter placebo-controlled parallel study to assess the safety and efficacy of intralesional interferon-α-2b for minimally invasive treatment for Peyronie’s disease. J Urol. 2006;176:394–8.

    Article  PubMed  CAS  Google Scholar 

  60. Levine LA, Lenting EL. Experience with a surgical algorithm for Peyronie’s disease. J Urol. 1997;158:2149–52.

    Article  PubMed  CAS  Google Scholar 

  61. Moncada I, Jara J, Marinez J. et al. Managing penile shortening after peyronie’s disease surgery [Abst 750]. Annual Meeting of the American Urological Association. Anaheim, CA; 2007.

    Google Scholar 

  62. Taylor FL, Levine LA. Surgical correction of Peyronie’s disease via tunica albuginea plication or plaque partial excision with pericardial graft: long term follow-up [Abst 748]. Annual Meeting of the American Urological Association. Anaheim, CA; 2007.

    Google Scholar 

  63. Kadioglu A, Sanli O, Akman T, et al. Graft materials in Peyronie’s disease surgery: a comprehensive review. J Sex Med. 2007;4:581–95.

    Article  PubMed  Google Scholar 

  64. Greenfield JM, Estrada CR, Levine LA. Erectile dysfunction following surgical correction of Peyronie’s disease and a pilot study of the use of sildenafil citrate rehabilitation for postoperative erectile dysfunction. J Sex Med. 2005;2:241–7.

    Article  PubMed  Google Scholar 

  65. Carson CC, Hodge GB, Anderson EE. Penile prosthesis in Peyronie’s disease. Br J Urol. 1983;55:417–21.

    Article  PubMed  CAS  Google Scholar 

  66. Ghanem HM, Fahmy I, El Meliegy A. Malleable penile implants without plaque surgery in the treatment of Peyronie’s disease. Int J Impot Res. 1998;10:171–3.

    Article  PubMed  CAS  Google Scholar 

  67. Levine LA, Dimitriou RJ. A surgical algorithm for penile prosthesis placement in men with erectile ­failure and Peyronie’s disease. Int J Impot Res. 2000;12:147–51.

    Article  PubMed  CAS  Google Scholar 

  68. Levine LA, Estrada CR, Morgentaler A. Mechanical reliability and safety of and patient satisfaction with the Ambicor inflatable penile prosthesis: results of a two center study. J Urol. 2001;166:932–7.

    Article  PubMed  CAS  Google Scholar 

  69. Montague DK, Angermeier KW, Lakin MM, Ingleright BJ. AMS 3-piece inflatable penile prosthesis implantation in men with Peyronie’s disease: comparison of CX and Ultrex cylinders. J Urol. 1996;156:1633–35.

    Article  PubMed  CAS  Google Scholar 

  70. Dowalczyk JJ, Mulcahy JJ. Penile curvatures and aneurismal defects with the Ultrex penile prosthesis corrected with insertion of the AMS 700CX. J Urol. 1996;156:398–401.

    Article  Google Scholar 

  71. Montorsi F, Rigatti P, Carmignani G, et al. AMS three-piece inflatable implants for erectile dysfunction: a long-term multi-institutional study in 200 consecutive patients. Eur Urol. 2000;37:50–5.

    Article  PubMed  CAS  Google Scholar 

  72. Daitch JA, Angermeier KW, Montague DK. Modified corporoplasty for penile curvature: long-term results and patient satisfaction. J Urol. 1999;162:2006–9.

    Article  PubMed  CAS  Google Scholar 

  73. Gholami SS, Lue TF. Correction of penile curvature using the 16-dot plication technique: a review of 132 patients. J Urol. 2002;167:2066–9.

    Article  PubMed  Google Scholar 

  74. Syed AH, Abbasi Z, Hargreave TB. Nesbit procedure for disabling Peyronie’s curvature: a median follow-up of 84 months. Urology. 2003;61:999–1003.

    Article  PubMed  Google Scholar 

  75. Savoca G, Scieri F, Pietropaolo F, et al. Straightening corporoplasty for Peyronie’s disease: a review of 218 patients with median follow-up of 89 months. Eur Urol. 2004;6:610–4.

    Article  Google Scholar 

  76. Rolle L, Tamagnone A, Timpano M, et al. The Nesbit operation for penile curvature: an easy and effective technical modification. J Urol. 2005;173:171–3.

    Article  PubMed  Google Scholar 

  77. Bella AJ, Beasley KA, Obied A, Brock GB. Minimally invasive intracorporeal incision of Peyronie’s plaque: initial experiences with a new technique. Urology. 2006;68:852–7.

    Article  PubMed  Google Scholar 

  78. Greenfield JM, Lucas S, Levine LA. Factors affecting the loss of length associated with tunica albuginea plication for correction of penile curvature. J Urol. 2006;175:238–41.

    Article  PubMed  Google Scholar 

  79. Taylor FL, Levine LA. Surgical correction of Peyronie’s disease via tunica albuginea plication or partial plaque excision with pericardial graft: long-term follow up. J Sex Med. 2008;5:2221–8.

    Article  PubMed  Google Scholar 

  80. Gelbard MK. Relaxing incisions in the correction of penile deformity due to Peyronie’s disease. J Urol. 1995;154:1457–60.

    Article  PubMed  CAS  Google Scholar 

  81. El-Sakka AI, Rashwan HM, Lue TF. Venous patch graft for Peyronie’s disease. Part II: outcome analysis. J Urol. 1998;160:2050–3.

    Article  PubMed  CAS  Google Scholar 

  82. Hatzichristou DG, Hatzimouratidis K, Apostolidis A, et al. Corporoplasty using tunica albuginea free grafts for penile curvature: surgical technique and long-term results. J Urol. 2002;167:1367–70.

    Article  PubMed  Google Scholar 

  83. Egydio PH, Lucon AM, Arap S. Treatment of Peyronie’s disease by incomplete circumferential incision of the tunica albuginea and plaque with bovine pericardium graft. Urology. 2002;59:570–4.

    Article  PubMed  Google Scholar 

  84. Levine LA, Estrada CR. Human cadaveric pericardial graft for the surgical correction of Peyronie’s disease. J Urol. 2003;170:2359–62.

    Article  PubMed  Google Scholar 

  85. Kalsi J, Minhas S, Christopher N, Ralph D. The results of plaque incision and venous grafting (Lue procedure) to correct the penile deformity of Peyronie’s disease. BJU Int. 2005;95:1029–33.

    Article  PubMed  Google Scholar 

  86. Breyer BN, Brant WO, Garcia MM, et al. Complications of porcine small intestine submucosa graft for Peyronie’s disease. J Urol. 2007;177:589–91.

    Article  PubMed  Google Scholar 

  87. Hsu GL, Chen HS, Hsieh CH, et al. Long-term results of autologous venous grafts for penile morphological reconstruction. J Androl. 2007;28:186–93.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Urology, Rush University Medical Center, 1653 West Congress Parkway, Suite 348, Professional Building, Chicago, IL, 60612, USA

    Frederick L. Taylor

Authors
  1. Frederick L. Taylor
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Laurence A. Levine
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Frederick L. Taylor .

Editor information

Editors and Affiliations

  1. Sexual Medicine Program, Memorial Sloan-Kettering Cancer Center, East 68th Street 353, New York, 10021, New York, USA

    John P. Mulhall

  2. Daniel den Hoed Cancer Center, Dept. Radiation Oncology, Erasmus Medical Center, Groene Hilledijk 301, Rotterdam, 3075 EA, Netherlands

    Luca Incrocci

  3. Alvarado Hospital, Alvarado Road 6719, San Diego, 92120, California, USA

    Irwin Goldstein

  4. New England Research Institutes, Galen Street 9, Watertown, 02472, Massachusetts, USA

    Ray Rosen

Rights and permissions

Reprints and permissions

Copyright information

© 2011 Springer Science+Business Media, LLC

About this chapter

Cite this chapter

Taylor, F.L., Levine, L.A. (2011). Peyronie’s Disease. In: Mulhall, J., Incrocci, L., Goldstein, I., Rosen, R. (eds) Cancer and Sexual Health. Current Clinical Urology. Humana Press. https://doi.org/10.1007/978-1-60761-916-1_15

Download citation

  • DOI: https://doi.org/10.1007/978-1-60761-916-1_15

  • Published:

  • Publisher Name: Humana Press

  • Print ISBN: 978-1-60761-915-4

  • Online ISBN: 978-1-60761-916-1

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation